68%
Finnrick rating
#200 of 283 ranked vendors
33 of 50 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Zhejiang Yichenkang Biotechnology's purity-focus record is strongest on Ipamorelin and GHK-Cu, while BPC-157 and Semaglutide show the clearest weak spots. The evidence is recent and moderate in volume, but results are dispersed rather than clearly improving, with sub-99.5% purity misses, fill swings, and absent batch IDs limiting traceability.

methodology →
vendor intelligence report
Vendor Intelligence Report: Zhejiang Yichenkang Biotechnology

We investigated who actually operates Zhejiang Yichenkang Biotechnology — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

21 pages4 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
86%
5
2
Ipamorelin
$0.70
80%
7
3
Retatrutide
$2.30
77%
12
4
Tirzepatide
$1.56
75%
9
5
Melanotan II
$0.64
65%
5
6
Semaglutide
$1.30
62%
7
7
CJC-1295
$1.60
44%
6
8
BPC-157
$0.64
40%
7
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%25 Jun 2025: 56%25 Jun 2025: 57%25 Jun 2025: 58%25 Jun 2025: 58%25 Jun 2025: 57%26 Jun 2025: 58%26 Jun 2025: 58%26 Jun 2025: 58%26 Jun 2025: 57%29 Jun 2025: 56%29 Jun 2025: 56%30 Jun 2025: 56%10 Jul 2025: 61%10 Jul 2025: 60%10 Jul 2025: 61%22 Jul 2025: 61%22 Jul 2025: 62%23 Jul 2025: 62%23 Jul 2025: 62%24 Jul 2025: 62%24 Jul 2025: 63%25 Jul 2025: 62%25 Jul 2025: 62%4 Aug 2025: 62%4 Aug 2025: 63%4 Aug 2025: 62%4 Aug 2025: 63%4 Aug 2025: 63%5 Aug 2025: 62%5 Aug 2025: 62%5 Aug 2025: 61%5 Sept 2025: 62%5 Sept 2025: 62%20 Sept 2025: 62%20 Sept 2025: 61%17 Oct 2025: 63%25 Nov 2025: 63%2 Dec 2025: 62%5 Dec 2025: 64%11 Dec 2025: 64%29 Jul 2026: current 68%56%63%68%Jun 25Jul 26
Zhejiang Yichenkang Biotechnology test history
COA-backed lab tests
1-10 of 58

About Zhejiang Yichenkang Biotechnology test results from Finnrick

Zhejiang Yichenkang Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 8 peptides and 58 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Zhejiang Yichenkang Biotechnology peptides in this dataset are CJC-1295 (6 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 58 recent tests.

Corrections
No corrections.